Welch Capital Partners LLC NY Sells 84,932 Shares of Henry Schein, Inc. $HSIC

Welch Capital Partners LLC NY lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 57.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,897 shares of the company’s stock after selling 84,932 shares during the quarter. Henry Schein comprises about 1.1% of Welch Capital Partners LLC NY’s investment portfolio, making the stock its 9th biggest position. Welch Capital Partners LLC NY’s holdings in Henry Schein were worth $4,709,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of HSIC. Parallel Advisors LLC raised its holdings in Henry Schein by 12.7% during the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company’s stock valued at $97,000 after buying an additional 148 shares in the last quarter. HB Wealth Management LLC increased its holdings in shares of Henry Schein by 1.3% during the 4th quarter. HB Wealth Management LLC now owns 15,034 shares of the company’s stock valued at $1,136,000 after acquiring an additional 191 shares during the last quarter. Czech National Bank raised its stake in shares of Henry Schein by 0.8% in the 4th quarter. Czech National Bank now owns 26,386 shares of the company’s stock valued at $1,994,000 after acquiring an additional 206 shares in the last quarter. Jain Global LLC lifted its holdings in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock worth $708,000 after purchasing an additional 207 shares during the last quarter. Finally, Sanctuary Advisors LLC boosted its position in Henry Schein by 4.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,856 shares of the company’s stock worth $367,000 after purchasing an additional 209 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Stock Performance

Shares of HSIC stock opened at $87.82 on Monday. The firm has a market capitalization of $10.00 billion, a P/E ratio of 26.53, a price-to-earnings-growth ratio of 1.69 and a beta of 0.81. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $89.34. The firm’s fifty day simple moving average is $79.50 and its 200 day simple moving average is $77.72. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The firm had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the firm earned $1.15 EPS. The business’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current year.

Insiders Place Their Bets

In other news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.89% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HSIC shares. Wall Street Zen lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. BMO Capital Markets initiated coverage on shares of Henry Schein in a report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 target price on the stock. Citigroup started coverage on shares of Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price for the company. BTIG Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Thursday, June 11th. Finally, Robert W. Baird set a $97.00 price target on Henry Schein in a research report on Wednesday, May 6th. Seven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $87.64.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.